Hospital course note4/6/2024 The full set of data would become available to the public at that time. Merck Thursday morning announced the results of an ongoing Phase 3 study are so compelling that an independent monitoring board recommended, in consultation with the FDA, ending the trial early so the companies can swiftly seek authorization. Having an effective pill to offer them would "make a difference," Del Rio added. Right now, most COVID-19 patients are sent home and told to monitor their symptoms. Carlos Del Rio, the executive associate dean and a global health expert at the Emory School of Medicine, said. Davis, the chief executive officer and president of Merck told "Good Morning America" Friday. "This is the first oral antiviral that will be available to combat COVID-19 and why that's so important, if you think of it if you're someone who is unfortunate enough to get the news that you've contracted COVID-19, this is the pill, you can take it home and will significantly reduce the risk that you either ultimately are hospitalized or more importantly that you would ever face the unfortunate outcome of death," Robert M.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |